Tourmaline Bio, INC

Tourmaline Bio, Inc. has completed its merger with Novartis AG, with shares acquired at $48.00 per share and delisting from Nasdaq initiated.

Tourmaline Bio, Inc. has amended its Executive Severance and Change in Control Plan, increasing benefits for its CFO and CBO/General Counsel in the event of a covered termination during a change in control period.

Novartis AG will acquire Tourmaline Bio, Inc. for $48.00 per share in cash, totaling approximately $1.4 billion, representing a significant premium for shareholders.

Tourmaline Bio announced positive topline results from its Phase 2 TRANQUILITY trial for pacibekitug and reported a cash runway into the second half of 2027.

Tourmaline Bio, Inc. reported positive topline data from its Phase 2 TRANQUILITY trial for pacibekitug in cardiovascular inflammation, demonstrating deep and sustained hs-CRP reductions with a favorable safety profile, while also outlining its strategic path forward for multiple indications.

Tourmaline Bio, Inc. announced the successful election of Dr. Caley Castelein and Aaron Kantoff as Class I directors and the ratification of Deloitte & Touche LLP as its independent auditor at its 2025 annual meeting of stockholders.

Tourmaline Bio, a late-stage clinical biotechnology company, announced positive topline data from its Phase 2 TRANQUILITY trial for pacibekitug in cardiovascular inflammation and extended its cash runway into the second half of 2027.

Tourmaline Bio, a late-stage clinical biotechnology company, announces its Q1 2025 financial results and provides updates on its ongoing clinical trials for pacibekitug.

Tourmaline Bio reports a net loss of $20.2 million for the third quarter of 2024, alongside significant increases in research and development spending.

Tourmaline Bio reports a net loss of $17.5 million for the second quarter of 2024, alongside updates on clinical trials and financial position.

Tourmaline Bio's first quarter 2024 report highlights increased spending on research and development, a successful public offering, and progress in clinical trials for their lead drug candidate, TOUR006.

Tourmaline Bio's 2024 10-K filing highlights the company's progress in developing pacibekitug for immune and inflammatory diseases, particularly ASCVD and TED, while acknowledging ongoing financial losses and future capital needs.

Tourmaline Bio's 10-K filing highlights the company's focus on developing TOUR006 for autoimmune and cardiovascular diseases, along with financial details and risk factors.

Tourmaline Bio director Clay B. Siegall disposed of all his employee stock options as part of the company's acquisition by Novartis AG for $48.00 per share.

Tourmaline Bio Director Parvinder Thiara disposed of all common stock and stock options as part of the company's acquisition by Novartis AG for $48.00 per share.

Tourmaline Bio director Sapna Srivastava disposed of all common stock and stock options following the completion of the acquisition by Novartis AG for $48.00 per share.

Mark McDade, a director of Tourmaline Bio, Inc., disposed of all his direct and indirect holdings and stock options following the company's acquisition by Novartis AG for $48.00 per share.

Tourmaline Bio Director Aaron Kantoff disposed of all common stock and cashed out stock options following the company's acquisition by Novartis AG for $48.00 per share.

Caley Castelein, a Director and 10% Owner of Tourmaline Bio, Inc., reported the disposition of common stock and options following the company's acquisition by Novartis AG for $48.00 per share.

Tourmaline Bio, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Tourmaline Bio will hold its annual stockholder meeting virtually on June 4, 2025, to elect directors and ratify the selection of its independent auditor.

Tourmaline Bio, Inc. has filed a definitive proxy statement with the SEC related to its upcoming shareholder meeting.

Tourmaline Bio will hold its Annual Meeting of Stockholders virtually on June 5, 2024, to elect directors and ratify the selection of its independent accounting firm.

RA Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Tourmaline Bio, Inc., holding 0% of the common stock as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.5% beneficial ownership stake in Tourmaline Bio, Inc.'s common stock.

QVT Financial LP has reported an 8.39% beneficial ownership stake in Tourmaline Bio, Inc., holding 2,154,653 shares of common stock.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 9.95% beneficial ownership stake in Tourmaline Bio, Inc. for investment purposes.

QVT Financial LP has filed a Schedule 13G, reporting a beneficial ownership of 5.74% of Tourmaline Bio, Inc.'s common stock as of March 31, 2025.

Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a 4.2% passive beneficial ownership stake in Tourmaline Bio, Inc. as of December 31, 2024.